Entity

Time filter

Source Type

Coventry, RI, United States

Jacob J.N.,Organomed Corporation | Badyal D.K.,Christian Medical College
Natural Product Communications | Year: 2014

Turmeric and fish oil have been gaining interest as food supplements because of their beneficial properties. Turmeric oil contains sesquiterpenes and fish oil has eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), possessing anti-inflammatory activity. The present study is to evaluate and compare the anti-inflammatory and analgesic properties of these two natural food products with aspirin as a standard. The percent inhibition as a measure of paw edema for turmeric oil and fish oil at 100 mg/kg was 76% and 31%, respectively, while the percent inhibition by the combination of the two at 100 mg/kg was 62%, which was the same as that of aspirin at the same dose. The inhibitory activity of fish oil at 50 mg/kg was 86% and with an increase in dose the activity decreased. The analgesic activity measured by the tail flick method showed optimum activities for turmeric oil and fish oil at 60 and 90 minutes, respectively, whereas the combination of the two decreased the analgesic activity. Thus the two common food ingredients, oils from turmeric and fish, have desirable biochemical properties to develop further their use as food and medicine. Source


Jacob J.N.,Organomed Corporation | Badyal D.K.,Christian Medical College | Bala S.,Christian Medical College | Toloue M.,Bioo Scientific Corporation
Natural Product Communications | Year: 2013

Curcumin, obtained from turmeric, has several biological properties to make it a desirable template for drug development. A lipophilic derivative of curcumin, diacetyl curcumin (DAC) and a hydrophilic derivative, diglutaryl curcumin (DGC) were synthesized and their in vivo analgesic and anti-inflammatory activities were compared with those of curcumin and aspirin. The in vitro anti-cancer activities of curcumin and the two derivatives against three cell cancer lines were compared with those against a non-cancerous cell line. The inhibitory effects were comparable to each other and nearing that of curcumin while they showed low inhibitory effect towards the non-cancerous cell line. The mouse tail flick assay showed that curcumin, DAC and DGC increased latency time. DGC was most effective as an analgesic, even more so than aspirin. The maximum percentage effect (MPE) was highest with DGC at 3 hours. The carrageenan induced paw edema model indicated anti-inflammatory activity of all three curcumin formulations. The percentage inhibition of paw edema was maximum for DAC, followed by aspirin and curcumin. Source


Jacob J.N.,Organomed Corporation | Toloue M.,Bioo Scientific Corporation
Natural Product Communications | Year: 2013

The oil from turmeric (Curcuma longa ) contains several sesquiterpenes with medicinal properties. The oil fractions were purified by repeated high vacuum distillations to constant boiling points and by column chromatography. The major components in the oil fractions were identified as α,β and ar-turmerones. The purified turmeric oil (TO) fractions had growth inhibitory activity against breast (SKBR-3), pancreatic (PANC-1), and prostate (PC-3) cancers, and reduced activity against a non-cancerous cell line, WI-38. A combination of the distillation fraction of turmeric oil and paclitaxel showed substantial increase in growth inhibitory activity against the three cancer cell lines compared with paclitaxel alone, while having reduced activity against the non-cancerous cell line. Percent inhibition may be related to the structural parameters of the turmerones. These results suggest that components in turmeric oil fractions have anticancer activity against breast, pancreatic and prostate cancer and a strong positive effect on the activity of paclitaxel. Source


Yan W.,Brown University | Bowen W.D.,Brown University | Hopson R.,Brown University | Mathew A.E.,Molecular Architect | Jacob J.N.,Organomed Corporation
Natural Product Communications | Year: 2013

The current study is directed at identifying compounds that have biological activity in the less studied oil fraction of Curcuma longa (turmeric) to treat pancreatic cancer, which has no good treatment options. Fractional distillation and chromatographic separation of turmeric oil (TO) gave column fractions (CF) having biological activity against the PANC-1 pancreatic cancer cell line, with an EC50 in the range of 23 to 33 μg/mL. These fractions were analyzed by NMR and GCMS and found to contain the sesquiterpenes, ar-curcumene, 7-epi-zingiberene, β-sesquiphellandrene, curlone, α-turmerone, β-turmerone and ar-turmerone. The ability of TO components to induce cell death was independent of caspase activity. Potency was higher at lower cell density and was reduced by increasing serum concentration, the latter indicating serum binding of active components. Source


Patent
Organomed Corporation | Date: 2012-06-29

The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.

Discover hidden collaborations